In vitro and in vivo activity of thiourea (ISO), a mycolic acid inhibitor, against multi drug resistant (MDR) strains of Mycobacterium tuberculosis (M. tb )Source: Eur Respir J 2005; 26: Suppl. 49, 700s Year: 2005
Minimal inhibitory concentrations (MIC) of first line drugs in multidrug resistant strains of M. tuberculosis (MDR-TB) Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010
In vitro and vivo study of isoxyl, a mycolic acid inhibitor for intermittent chemotherapy of multi drug resistant (MDR) strains of mycobacterium tuberculosis (M.tb)Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT) Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Primary multidrug resistance (PMDR) of mycobacterium tuberculosis (MBT) to antimycobacterial drugs (AMBTD) in the patients with destructive TB. Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Biological properties of Mycobacterium tuberculosis (Mtb) resistant to biocides Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Laboratory system to detect multidrug-resistant (MDR) and extensively drug-resistant (XDR) mycobacterium tuberculosis strains in clinical practice Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008
Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) : global response Source: International Congress 2017 – Update on TB: latest news Year: 2017
Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Phenotypic resistance of M. tuberculosis to bedaquilin (BDQ) and linezolid (LZD) Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021
Express diagnostics of mycobacterium tuberculosis (MBT) drug resistance at disseminated tuberculosis (DT) Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives Year: 2008
Line probe assay (LiPA) based rapid detection of multiple drug resistent (MDR) mycobacterium tuberculosis (MTB) Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: epidemiology, diagnosis and treatment Source: Annual Congress 2008 - Infection year in review Year: 2008
Infection of the respiratory mucosa by Mycobacterium avium complex (MAC), Mycobacterium tuberculosis (MTB) and Mycobacterium smegmatis (MS) Source: Eur Respir J 2001; 18: Suppl. 33, 308s Year: 2001
Estimation of susceptibility hospital strains of Mycobacterium tuberculosis (Mtb) Beijing to disinfectants Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010
Deficient in silico selection of mycobacterium tuberculosis (MTB) epitopes in tuberculosis (TB) patients Source: Eur Respir J 2006; 28: Suppl. 50, 801s Year: 2006
Induction of M. tuberculosis (MTB) drug resistance (DR) mutations in HIV-infected hosts and pathways of further spread of the evolutionary successful drug-resistant MTB clonal lines Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020